crinecerfont
Drug Details
- Generic Name
- crinecerfont
- Brand Names
- Crenessity
- Application Number
- NDA218808
- Sponsor
- Neurocrine Biosciences, Inc.
- NDC Codes
- 4
- Dosage Forms
- CAPSULE, SOLUTION
- Routes
- ORAL
- Active Ingredients
- CRINECERFONT
Indications and Usage
1 INDICATIONS AND USAGE CRENESSITY is indicated as adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH) . CRENESSITY is a corticotropin-releasing factor type 1 receptor antagonist indicated as adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).